Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 October 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 August 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 July 2021
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2020
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 May 2019
Padeliporfin for untreated localised prostate cancer (TA546)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 November 2018
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 August 2016Published: 25 May 2016
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 27 July 2016Published: 27 April 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2006
Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 November 2022
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 24 May 2023
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 11 October 2023
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone refractory) - atrasentan [ID390]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (prevention) - dutasteride [ID75]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enzalutamide for the treatment of hormone refractory prostate cancer TA316Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID 5103]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy TS ID 9716Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC